Eduardo Pérez-Gómez

Prof. Dr. Eduardo Pérez-Gómez

Biochemistry ¬ Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MSMaría Salazar
María Salazar
ACArkaitz Carracedo
Arkaitz Carracedo
ÍSÍñigo J. Salanueva
Íñigo J. Salanueva
SHSonia Hernández-Tiedra
Sonia Hernández-Tiedra
MLMar Lorente
Mar Lorente
GDGuillermo Velasco Díez
Guillermo Velasco Díez
Autophagy can promote cell survival or cell death, but the molecular basis underlying its dual role in cancer remains obscure. Here we demonstrate that Δ9-tetrahydrocannabinol (THC), the main active component of marijuana, induces human glioma cell death through stimulation of autophagy. Our data indicate that THC induced ceramide accumulation and eukaryotic translation initiation factor 2α (eIF2α) phosphorylation and thereby activated an ER stress response that promoted autophagy via tribbles homolog 3–dependent (TRB3-dependent) inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis. We also showed that autophagy is upstream of apoptosis in cannabinoid-induced human and mouse cancer cell death and that activation of this pathway was necessary for the antitumor action of cannabinoids in vivo. These findings describe a mechanism by which THC can promote the autophagic death of human and mouse cancer cells and provide evidence that cannabinoid administration may be an effective therapeutic strategy for targeting human cancers.

1 July 2006 in Cancer Research
Verified
Journal Article
Closed access
ACArkaitz Carracedo
Arkaitz Carracedo
MGMeritxell Gironella
Meritxell Gironella
MLMar Lorente
Mar Lorente
SGStephane Garcia
Stephane Garcia
MGManuel Guzmán
Manuel Guzmán
JIJuan L. Iovanna
Juan L. Iovanna
Pancreatic adenocarcinomas are among the most malignant forms of cancer and, therefore, it is of especial interest to set new strategies aimed at improving the prognostic of this deadly disease. The present study was undertaken to investigate the action of cannabinoids, a new family of potential antitumoral agents, in pancreatic cancer. We show that cannabinoid receptors are expressed in human pancreatic tumor cell lines and tumor biopsies at much higher levels than in normal pancreatic tissue. Studies conducted with MiaPaCa2 and Panc1 cell lines showed that cannabinoid administration (a) induced apoptosis, (b) increased ceramide levels, and (c) up-regulated mRNA levels of the stress protein p8. These effects were prevented by blockade of the CB2 cannabinoid receptor or by pharmacologic inhibition of ceramide synthesis de novo. Knockdown experiments using selective small interfering RNAs showed the involvement of p8 via its downstream endoplasmic reticulum stress–related targets activating transcription factor 4 (ATF-4) and TRB3 in Δ9-tetrahydrocannabinol–induced apoptosis. Cannabinoids also reduced the growth of tumor cells in two animal models of pancreatic cancer. In addition, cannabinoid treatment inhibited the spreading of pancreatic tumor cells. Moreover, cannabinoid administration selectively increased apoptosis and TRB3 expression in pancreatic tumor cells but not in normal tissue. In conclusion, results presented here show that cannabinoids lead to apoptosis of pancreatic tumor cells via a CB2 receptor and de novo synthesized ceramide-dependent up-regulation of p8 and the endoplasmic reticulum stress–related genes ATF-4 and TRB3. These findings may contribute to set the basis for a new therapeutic approach for the treatment of pancreatic cancer. (Cancer Res 2006; 66(13): 6748-55)

1 April 2006 in Cancer Cell
Verified
Journal Article
Closed access
ACArkaitz Carracedo
Arkaitz Carracedo
MLMar Lorente
Mar Lorente
AEAinara Egia
Ainara Egia
CBCristina Blázquez
Cristina Blázquez
SGStephane García
Stephane García
GDGuillermo Velasco Díez
Guillermo Velasco Díez

1 January 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
STSofía Torres
Sofía Torres
MLMar Lorente
Mar Lorente
FRFátima Rodríguez-Fornés
Fátima Rodríguez-Fornés
SHSonia Hernández-Tiedra
Sonia Hernández-Tiedra
MSMaría Salazar
María Salazar
GDGuillermo Velasco Díez
Guillermo Velasco Díez
Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ9-Tetrahydrocannabinol (THC), the major active ingredient of marijuana, and other cannabinoid receptor agonists inhibit tumor growth in animal models of cancer, including glioma, an effect that relies, at least in part, on the stimulation of autophagy-mediated apoptosis in tumor cells. Here, we show that the combined administration of THC and temozolomide (TMZ; the benchmark agent for the management of GBM) exerts a strong antitumoral action in glioma xenografts, an effect that is also observed in tumors that are resistant to TMZ treatment. Combined administration of THC and TMZ enhanced autophagy, whereas pharmacologic or genetic inhibition of this process prevented TMZ + THC-induced cell death, supporting that activation of autophagy plays a crucial role on the mechanism of action of this drug combination. Administration of submaximal doses of THC and cannabidiol (CBD; another plant-derived cannabinoid that also induces glioma cell death through a mechanism of action different from that of THC) remarkably reduces the growth of glioma xenografts. Moreover, treatment with TMZ and submaximal doses of THC and CBD produced a strong antitumoral action in both TMZ-sensitive and TMZ-resistant tumors. Altogether, our findings support that the combined administration of TMZ and cannabinoids could be therapeutically exploited for the management of GBM. Mol Cancer Ther; 10(1); 90–103. ©2011 AACR.

1 December 2014 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
VCValentina Cianfanelli
Valentina Cianfanelli
CFClaudia Fuoco
Claudia Fuoco
MLMar Lorente
Mar Lorente
MSMaria Salazar
Maria Salazar
FQFabio Quondamatteo
Fabio Quondamatteo
FCFrancesco Cecconi
Francesco Cecconi
Inhibition of a main regulator of cell metabolism, the protein kinase mTOR, induces autophagy and inhibits cell proliferation. However, the molecular pathways involved in the cross-talk between these two mTOR-dependent cell processes are largely unknown. Here we show that the scaffold protein AMBRA1, a member of the autophagy signalling network and a downstream target of mTOR, regulates cell proliferation by facilitating the dephosphorylation and degradation of the proto-oncogene c-Myc. We found that AMBRA1 favours the interaction between c-Myc and its phosphatase PP2A and that, when mTOR is inhibited, it enhances PP2A activity on this specific target, thereby reducing the cell division rate. As expected, such a de-regulation of c-Myc correlates with increased tumorigenesis in AMBRA1-defective systems, thus supporting a role for AMBRA1 as a haploinsufficient tumour suppressor gene.

15 June 1999 in The EMBO Journal
Verified
Journal Article
Closed access
EGEmiliano García
Emiliano García
CMCamelia Marcos‐Gutiérrez
Camelia Marcos‐Gutiérrez
MLMar Lorente
Mar Lorente
JMJuan Carlos Moreno
Juan Carlos Moreno
MVMiguel Vidal
Miguel Vidal